Beam Therapeutics Inc.の将来のP / EはN/Aです。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.